

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Daniel Rajotte, et al	)	Confirm. No.:	3401
Serial No.:	10/637,887	)	Art Unit:	1652
Filed:	August 8, 2003	)	Examiner:	Delia M. Ramirez
For:	Methods and compositions for targeting secretory lysosomes			
Docket No.:	9/251			

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REPLY TO RESTRICTION REQUIREMENT**

Sir:

This is in response to a communication from the Examiner in charge of the subject application, which communication was mailed on March 8, 2006. In that Office Action, a one-month shortened statutory period was set for response. Thus, this reply is timely. However, if it is determined that an extension of time is necessary, applicants hereby petition for the necessary extension of time under 37 C.F.R. § 1.136 to respond to that action. Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Amendment, authorization is hereby given to charge such fees to Deposit Account No. 02-2955. In addition, applicants also request that any subsequently filed reply requiring a petition for an extension of time for its timely submission be treated as if it incorporated such petition for an extension of time pursuant to the provisions of 37 C.F.R. § 1.136(a)(3) and hereby authorize that any fees due in connection therewith be charged to Deposit Account No. 02-2955.

Claims 1-26 are pending.

In the communication mailed March 8, 2006, the Examiner imposed a restriction requirement in the instant application. Applicants hereby elect Group V, claims 3-4, and 6-11, drawn in part to a polynucleotide encoding a fusion protein comprising a chymase that specifically localizes to a secretory lysosome and a label polypeptide, and a cell transformed with said polynucleotide with traverse. Applicants request that the Examiner join claims 5 and 12. Claim 5 is directed to a secretory lysosome targeting fusion moiety wherein the protease is Rat Mast Cell Protease (RMCP) II. As disclosed on page 3, second paragraph of the specification Rat Mast Cell Protease (RMCP) II is a chymase. Claim 12

Application No. 10/637,887  
Reply dated April 3, 2006  
Reply to Office action of March 8, 2006

is directed to a cell line expressing a secretory lysosome targeting fusion moiety as deposited with ATCC and assigned accession number PTA-4571. As disclosed in the specification on page 11, first paragraph, PTA-4571 is a cell line expressing a secretory lysosome targeting moiety is designated RBL-RMCP/2C2 (a chymase).

In view of the foregoing, it is respectfully submitted that the subject application is in condition for allowance and such favorable action at an early date is earnestly solicited.

Respectfully submitted,

/Paula K. Wittmayer/

Paula K. Wittmayer  
Attorney for Applicant(s)  
Reg. No. 53,785

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT 06877  
Tel.: (203) 791-6692  
Fax: (203) 798-4408  
Dated: April 3, 2006